MA52249A - Antagonistes de l'intégrine humaine (alpha4) (beta7) - Google Patents
Antagonistes de l'intégrine humaine (alpha4) (beta7)Info
- Publication number
- MA52249A MA52249A MA052249A MA52249A MA52249A MA 52249 A MA52249 A MA 52249A MA 052249 A MA052249 A MA 052249A MA 52249 A MA52249 A MA 52249A MA 52249 A MA52249 A MA 52249A
- Authority
- MA
- Morocco
- Prior art keywords
- beta7
- alpha4
- integrin antagonists
- human integrin
- human
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/18—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862656742P | 2018-04-12 | 2018-04-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA52249A true MA52249A (fr) | 2021-05-05 |
Family
ID=68161020
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA052249A MA52249A (fr) | 2018-04-12 | 2019-04-12 | Antagonistes de l'intégrine humaine (alpha4) (beta7) |
Country Status (8)
Country | Link |
---|---|
US (3) | US10759756B2 (fr) |
EP (1) | EP3773573A4 (fr) |
JP (2) | JP7365358B2 (fr) |
CN (1) | CN112312910A (fr) |
AR (1) | AR114489A1 (fr) |
MA (1) | MA52249A (fr) |
TW (1) | TW202003466A (fr) |
WO (1) | WO2019200202A1 (fr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR114489A1 (es) * | 2018-04-12 | 2020-09-09 | Morphic Therapeutic Inc | ANTAGONISTAS DE LA INTEGRINA a4b7 HUMANA |
KR102641718B1 (ko) | 2018-10-30 | 2024-02-29 | 길리애드 사이언시즈, 인코포레이티드 | 알파4베타7 인테그린 억제제로서의 이미다조피리딘 유도체 |
AU2019373240B2 (en) | 2018-10-30 | 2023-04-20 | Gilead Sciences, Inc. | Quinoline derivatives as alpha4beta7 integrin inhibitors |
AU2019373242B2 (en) | 2018-10-30 | 2023-07-13 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
CN112969504B (zh) | 2018-10-30 | 2024-04-09 | 吉利德科学公司 | 用于抑制α4β7整合素的化合物 |
WO2021030438A1 (fr) | 2019-08-14 | 2021-02-18 | Gilead Sciences, Inc. | Composés pour l'inhibition de l'intégrine alpha 4 bêta 7 |
EP4045039A4 (fr) * | 2019-10-16 | 2023-12-13 | Morphic Therapeutic, Inc. | Inhibition de l'intégrine humaine alpha4beta7 |
WO2023125182A1 (fr) * | 2021-12-27 | 2023-07-06 | 海思科医药集团股份有限公司 | Dérivé d'acide propionique et son utilisation médicale |
WO2024051819A1 (fr) * | 2022-09-09 | 2024-03-14 | 西藏海思科制药有限公司 | Dérivé d'acide propionique et son utilisation en médecine |
WO2024138042A1 (fr) * | 2022-12-22 | 2024-06-27 | Xinthera, Inc. | Antagonistes de l'intégrine alpha4 bêta7 et leurs utilisations |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US5721366A (en) * | 1993-03-31 | 1998-02-24 | G. D. Searle & Co | Platelet aggregation inhibitors |
DE4427979A1 (de) * | 1993-11-15 | 1996-02-15 | Cassella Ag | Substituierte 5-Ring-Heterocyclen, ihre Herstellung und ihre Verwendung |
US5849736A (en) * | 1993-11-24 | 1998-12-15 | The Dupont Merck Pharmaceutical Company | Isoxazoline and isoxazole fibrinogen receptor antagonists |
BR9408137A (pt) * | 1993-11-24 | 1997-08-12 | Du Pont Merck Pharma | Composto éster de prodroga método de tratamento composição farmacêutica e método de inibição |
DE19622489A1 (de) | 1996-06-05 | 1997-12-11 | Hoechst Ag | Salze des 3-(2-(4-(4-(Amino-imino-methyl)-phenyl)-4- methyl-2,5-dioxo-imidazolidin-1-yl)-acetylamino)-3- phenyl-propionsäure-ethylesters |
US5981546A (en) * | 1996-08-29 | 1999-11-09 | Merck & Co., Inc. | Integrin antagonists |
CA2268270A1 (fr) | 1996-10-11 | 1998-04-23 | Cor Therapeutics, Inc. | Derives heterocycliques utilises comme inhibiteurs de facteur xa |
CA2268381A1 (fr) | 1996-10-11 | 1998-04-23 | Cor Therapeutics, Inc. | Inhibiteurs selectifs du facteur xa |
DE19751251A1 (de) * | 1997-11-19 | 1999-05-20 | Hoechst Marion Roussel De Gmbh | Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate |
US6645939B1 (en) | 1997-11-24 | 2003-11-11 | Merck & Co., Inc. | Substituted β-alanine derivatives as cell adhesion inhibitors |
MY153569A (en) | 1998-01-20 | 2015-02-27 | Mitsubishi Tanabe Pharma Corp | Inhibitors of ?4 mediated cell adhesion |
DE19821483A1 (de) * | 1998-05-14 | 1999-11-18 | Hoechst Marion Roussel De Gmbh | Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
CA2333647A1 (fr) * | 1998-06-29 | 2000-01-06 | Dupont Pharmaceuticals Company | Isoxazolidines et carbamates cycliques utilises comme antagonistes de iib/iiia |
GB9826174D0 (en) * | 1998-11-30 | 1999-01-20 | Celltech Therapeutics Ltd | Chemical compounds |
EP1189881B2 (fr) | 1999-05-07 | 2013-01-23 | Encysive Pharmaceuticals, Inc. | Derives de l'acide propanoique inhibant la liaison des integrines a leurs recepteurs |
US6972296B2 (en) | 1999-05-07 | 2005-12-06 | Encysive Pharmaceuticals Inc. | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors |
US6723711B2 (en) | 1999-05-07 | 2004-04-20 | Texas Biotechnology Corporation | Propanoic acid derivatives that inhibit the binding of integrins to their receptors |
IL148544A0 (en) | 1999-09-24 | 2002-09-12 | Genentech Inc | Tyrosine derivatives |
DE10041423A1 (de) | 2000-08-23 | 2002-03-07 | Merck Patent Gmbh | Biphenylderivate |
DE10111876A1 (de) * | 2001-03-10 | 2002-09-19 | Aventis Pharma Gmbh | Bis(trifluormethyl)hydantoine als Zwischenprodukte für pharmazeutische Wirkstoffe |
DE10154280A1 (de) | 2001-11-05 | 2003-05-15 | Wilex Ag | Antagonisten für alpha¶4¶-Integrine |
SI2336184T1 (sl) | 2002-02-25 | 2015-04-30 | Biogen Idec Ma Inc. | Dajanje sredstev za zdravljenje vnetij |
HUE058817T2 (hu) | 2004-09-03 | 2022-09-28 | Genentech Inc | Humanizált anti-béta7 antagonisták és alkalmazásaik |
ES2387317T3 (es) | 2005-03-03 | 2012-09-20 | Seedlings Life Science Ventures, Llc. | Procedimiento de control de riesgos de pacientes en tratamiento con natalizumab |
WO2006126529A1 (fr) | 2005-05-25 | 2006-11-30 | Shionogi & Co., Ltd. | Derive de morphinane substitue en position 7 par un carbamoyle et insature en positions 6 et 7 |
ATE496041T1 (de) | 2005-06-09 | 2011-02-15 | Ucb Pharma Sa | 2,6-chinolinderivate sowie verfahren zu ihrer herstellung und verwendung als arzneimittel |
EP4276469A3 (fr) | 2006-02-28 | 2024-01-17 | Biogen MA Inc. | Procédés de traitement de maladies inflammatoires et auto-immunes avec du natalizumab |
WO2010091411A1 (fr) | 2009-02-09 | 2010-08-12 | Glaxosmithkline Llc | Agents antiviraux à base de pipéridinyle amido cyclique |
MY189494A (en) | 2011-03-31 | 2022-02-16 | Genentech Inc | Methods of administering beta7 integrin antagonists |
RU2015112024A (ru) | 2012-10-05 | 2016-11-27 | Дженентек, Инк. | Способы диагностики и лечения воспалительного заболевания кишечника |
RU2016136716A (ru) | 2014-03-27 | 2018-04-28 | Дженентек, Инк. | Способы диагностики и лечения воспалительного заболевания кишечника |
WO2016011940A1 (fr) | 2014-07-25 | 2016-01-28 | 江苏恒瑞医药股份有限公司 | Dérivé d'indole-amide, son procédé de préparation et son application en médecine |
JP2018507868A (ja) | 2015-02-26 | 2018-03-22 | ジェネンテック, インコーポレイテッド | インテグリンベータ7アンタゴニスト及びクローン病の治療方法 |
US10246451B2 (en) | 2017-04-26 | 2019-04-02 | Aviara Pharmaceuticals, Inc. | Propionic acid derivatives and methods of use thereof |
AR114489A1 (es) | 2018-04-12 | 2020-09-09 | Morphic Therapeutic Inc | ANTAGONISTAS DE LA INTEGRINA a4b7 HUMANA |
AU2019373242B2 (en) | 2018-10-30 | 2023-07-13 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
AU2019373240B2 (en) | 2018-10-30 | 2023-04-20 | Gilead Sciences, Inc. | Quinoline derivatives as alpha4beta7 integrin inhibitors |
KR102641718B1 (ko) | 2018-10-30 | 2024-02-29 | 길리애드 사이언시즈, 인코포레이티드 | 알파4베타7 인테그린 억제제로서의 이미다조피리딘 유도체 |
CN112969504B (zh) | 2018-10-30 | 2024-04-09 | 吉利德科学公司 | 用于抑制α4β7整合素的化合物 |
EP4045039A4 (fr) | 2019-10-16 | 2023-12-13 | Morphic Therapeutic, Inc. | Inhibition de l'intégrine humaine alpha4beta7 |
-
2019
- 2019-04-12 AR ARP190100980A patent/AR114489A1/es unknown
- 2019-04-12 WO PCT/US2019/027141 patent/WO2019200202A1/fr unknown
- 2019-04-12 US US16/382,512 patent/US10759756B2/en active Active
- 2019-04-12 CN CN201980033206.5A patent/CN112312910A/zh active Pending
- 2019-04-12 MA MA052249A patent/MA52249A/fr unknown
- 2019-04-12 JP JP2020555323A patent/JP7365358B2/ja active Active
- 2019-04-12 EP EP19785592.7A patent/EP3773573A4/fr active Pending
- 2019-04-12 TW TW108112877A patent/TW202003466A/zh unknown
-
2020
- 2020-07-27 US US16/939,812 patent/US11174228B2/en active Active
-
2021
- 2021-11-12 US US17/525,479 patent/US20220340529A1/en not_active Abandoned
-
2023
- 2023-10-06 JP JP2023174330A patent/JP2024001201A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2024001201A (ja) | 2024-01-09 |
TW202003466A (zh) | 2020-01-16 |
EP3773573A1 (fr) | 2021-02-17 |
CN112312910A (zh) | 2021-02-02 |
JP2021531234A (ja) | 2021-11-18 |
US10759756B2 (en) | 2020-09-01 |
JP7365358B2 (ja) | 2023-10-19 |
AR114489A1 (es) | 2020-09-09 |
EP3773573A4 (fr) | 2022-04-06 |
WO2019200202A1 (fr) | 2019-10-17 |
US11174228B2 (en) | 2021-11-16 |
US20190315692A1 (en) | 2019-10-17 |
US20220340529A1 (en) | 2022-10-27 |
US20200385352A1 (en) | 2020-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA52249A (fr) | Antagonistes de l'intégrine humaine (alpha4) (beta7) | |
MA49990A (fr) | Récepteurs de liaison à l'antigène améliorés | |
MA46180A (fr) | Analogues de l'amyline | |
MA53218A (fr) | Antagonistes de l'intégrine | |
MA51232A (fr) | Indane-amines utiles en tant qu'antagonistes de pd-l1 | |
EP3836982C0 (fr) | Système de nettoyage d'endoscope intégré | |
DK3720433T3 (da) | Bis-cholin-tetrathiomolybdat til behandling af wilsons sygdom | |
EP4019691C0 (fr) | Appareil d'entretien de vêtements | |
SG11202008032YA (en) | Novel calcium salt polymorphs as anti-inflammatory, immunomodulatory and anti-proliferatory agents | |
MA50047A (fr) | Administration orale d'analogues peptidiques de glp-1 | |
MA53924A (fr) | Modulateurs de l'expression d'apol1 | |
MA50962A (fr) | Ensemble de prise d'empreinte dentaire | |
MA43764A (fr) | Inhibiteur monovalent de l'interaction hutnfr1 | |
IT201700123080A1 (it) | Macchina per l'assemblaggio di dispositivi medicali. | |
IT201700035964A1 (it) | “divisorio per boiserie” | |
MA51199A (fr) | Agents d'imagerie | |
UA38485S (uk) | Інтер'єр закладу торгівлі | |
UA39162S (uk) | Інтер'єр закладу торгівлі | |
UA37095S (uk) | Перев'язувальна пов'язка-бандаж | |
ES1228069Y (es) | "Valla de seguridad" | |
UA36907S (uk) | Комбінезон жіночий для вагітних | |
CA192139S (en) | Medical pet clothing | |
UA39715S (uk) | Сумка жіноча | |
UA39610S (uk) | Сумка жіноча | |
IT201700090331A1 (it) | "lopemide" |